Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zynerba Pharmaceuticals, Inc. - Common Stock (NQ:ZYNE)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 10, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zynerba Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  On Friday, 135 companies reached new 52-week lows. 
Via Benzinga
ZYNE: Nano-Cap Company That Is Focused On Treatments For Neuropsychiatric Disorders
Given the progress of its clinical trials, and its latest quarterly financials, Zynerba appears to be an excellent buy-and-hold investment consideration. 
Via Talk Markets
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
What's The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New Paper
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), announced the publication of a paper entitled, “Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol... 
Via Benzinga
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 258 companies hit new 52-week lows. 
Via Benzinga
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
CBD-Based Zygel Helps With Anxiety-Related & Behavioral Symptoms In 22q11.2 Deletion Syndrome, Phase 2 Trial Reveals
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) presented positive long-term 38-week data from the phase 2 INSPIRE trial with Zygel in children and adolescents with 22q11.2 deletion syndrome. 
Via Benzinga
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cannabis Legalization In Germany And Thailand, Gray Market In Brooklyn, Craft Weed Companies In Oregon
German Opposition Official Against Recreational Marijuana Legalization Plan 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 70 companies set new 52-week lows. 
Via Benzinga
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), released financial results for the third quarter ended September 30, 2022. Q3 2022 Financial Highlights 
Via Benzinga
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
A Comparison Of 5 Psychedelic ETFs And Indices
A look at 2 psychedelic ETFs and 3 tracking (non-trading) indices in the sector. 
Via Talk Markets
The Psychedelic Drug Stocks Index Continued To Plummet Last Week
In total, the Psychedelic Drug Stock Index went down 5.8% last week and is now down 64.9% YTD. 
Via Talk Markets
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
October Recap: Major Psychedelic Drug Stocks Declined 9.9%
In total, thePsychedelic Drug Stock Index went down 9.9% in September and is now down 64.7% YTD. 
Via Talk Markets
Cannabis Category Performances Ranged From +14.4% To -4.6% This Past Week
The 5 categories in the cannabis sector perform quite differently week to week. Below is a summary of how each category performed last week, in descending order and since the end of September and since... 
Via Talk Markets
Major Psychedelic Stock Downward Trend Continues
The 8 constituents of our Psychedelic Drug Stocks Index continue to collectively show poor performance, down 4.6% more last week and now down 45.5% since the end of August. 
Via Talk Markets
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.